Thyroid cancer is the most common endocrine cancer. The discovery of new biomarkers for
thyroid cancer has significantly improved the understanding of the molecular pathogenesis …

Thyroid cancer (TC) is the most prevalent endocrine malignant tumor. Surgery,
chemotherapy, radiotherapy, and radioactive iodine (RAI) therapy are the standard TC …

Increased understanding of disease-specific molecular targets of therapy has led to the
regulatory approval of two drugs (vandetanib and cabozantinib) for the treatment of …

Thyroid cancer comprises different clinical and histological entities. Whereas differentiated
(DTCs) malignancies are sensitive to radioiodine therapy, anaplastic (ATCs) and medullary …

Thyroid cancer is a frequently encountered endocrine malignancy. Despite the favorable
prognosis of this disease, 15–20% of differentiated thyroid cancer (DTC) cases and most …

Advanced differentiated thyroid cancer (DTC), defined by clinical characteristics including
gross extrathyroidal invasion, distant metastases, radioiodine (RAI) resistance, and avidity …

Therapeutic options for advanced, unresectable radioiodine-resistant thyroid cancers have
historically been limited. Recent progress in understanding the pathogenesis of the various …

The incidence of thyroid cancer is rapidly increasing, mostly due to the overdiagnosis and
overtreatment of differentiated thyroid cancer (TC). The increasing use of potent preclinical …

Differentiated thyroid cancer (DTC) is the most common endocrinological malignancy. There
are several histological variants such as papillary and follicular thyroid carcinoma. Many …

Whole genome sequencing approaches have provided unprecedented insights into the
genetic lesions responsible for the onset, progression and dedifferentiation of various types …